The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 8, 2000, Pages 836-843

  Massarella, J W ^a   He, G Z ^b   Dorr, A ^b   Nieforth, K ^a   Ward, P ^c   Brown, A ^c  

^a HOFFMANN LA ROCHE INC   (United States)

^b Roche Global Development   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; INFLUENZA; INFLUENZA VIRUS; MALE; METABOLITE; NORMAL HUMAN; STEADY STATE;

EID: 0033663158     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009567     Document Type: Article

References (15)

1. The effectiveness of vaccination against influenza in healthy working adults
2. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
3. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine
4. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase
5. Rational design of potent sialidase-based inhibitors of influenza virus replication
6. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity
7. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
8. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071
9. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104
10. Distribution of the influenza neuraminidase inhibitor GS4071, following oral administration of its prodrug GS4104 in ferrets (abstract)
11. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802
12. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection
13. In vitro activity of the neuraminidase inhibitor GS 4071 against influenza viruses
14. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor
15. Enhanced delivery of the novel influenza neuraminidase inhibitor GS4071 to rat lung after oral administration of the prodrug GS4104 (abstract)